Mumbai-based healthtech company HealWell24 has entered a new era. Acquired by Indocoast Management Consulting through a cash and stock deal, this development highlights the rapid transformation of the digital healthcare space in India. HealWell24, now rebranded as Vioma Lifesciences, represents a shift from homecare services to cutting-edge digital healthcare solutions, diagnostics, and MedTech innovations.
HealWell24 was a healthtech company based in Mumbai, India that was founded in 2017. It specialized in initial Home Healthcare with technology-enabled healthcare services, including AI analytics and Later Digital Healthcare Telemedicine, Healthcare Commerce and Patient Services at Doctors and Its Financing network with Doctors, Hospitals and Patient Community DPN
In September 2022, HealWell24 joined hands with Indocoast Management Consulting. This partnership helped the company become stronger and improve its financial and business systems.
By March 2023, Indocoast acquired a 65% majority stake, which later increased to 78% by September 2024. The deal brought substantial investments, enabling HealWell24 to scale its services and align with future market demands.
The rebranding of HealWell24 to Vioma Lifesciences is more than a name change. It represents a bold vision for the future. The company has shifted its focus from homecare to building a robust digital healthcare network. Vioma Lifesciences now prioritises digital diagnostics, MedTech solutions, and healthcare commerce, aiming to provide seamless medical services through advanced technology. This shift aligns with India’s growing emphasis on telehealth and medical innovation.
Founder and CEO Mr. JK Singha has played very important in this transformation since its inception. He served as the company’s chief operating officer (COO) until September 2024. Now he is a non-executive director and advisor in October 2024. Both Co-founders including RK Devi & Chittranjan Mishra, post-acquisition exited.
The acquisition has set the stage for a significant transformation. By March 2026, Vioma Lifesciences plans to complete its integration with its parent company, Indocoast. The focus will shift entirely to digital diagnostics, MedTech solutions, and healthcare commerce.
The homecare model, which was once a cornerstone of HealWell24, will be discontinued. Instead, resources will be channelled into building an ecosystem that supports telemedicine, diagnostics labs, and cutting-edge healthcare products.
While the exact details of the cash and stock deal remain confidential, industry estimates highlight its significance. HealWell24 previously raised $2.1 million in funding during its Series A round.
The deal structure reflects a long-term vision, with complete acquisition expected by March 2026. This gradual approach ensures smooth transitions in leadership, operations, and strategy.
The rebranding to Vioma Lifesciences is a strategic move. The new name reflects the company’s ambitions to lead in MedTech innovation and digital healthcare. This includes offering diagnostic tests, telehealth services, and even healthcare products through an integrated online platform.
Transitioning from homecare to a full-fledged digital healthcare and diagnostics aggregator comes with challenges. Building a strong network of diagnostics labs and healthcare commerce platforms requires significant investments and technological upgrades. The next few years will be crucial for Vioma Lifesciences. The company plans to Expand its digital diagnostics network, Invest in MedTech innovations and focus on healthcare commerce to make services affordable and accessible.
The transaction has been advised by R M and Associates and NFGi Partners led by Vishal Sg. Vioma Lifesciences journey from HealWell24 to becoming a digital healthcare pioneer showcases the potential of innovation and strategic partnerships.
